Another study indicated that bufalin could inhibit CRC progression by inhibiting SRC-1 and its regulated Hedgehog signalling; in particular, the authors demonstrated that bufalin could increase the therapeutic efficacy of the Hedgehog pathway-targeting drug vismodegib in CRC [16]. This evidence concerns the gene NCOA1 and colorectal carcinoma.